Why the study?
Does transcatheter aortic valve implantation (TAVI) improve haemodynamic and clinical outcomes in high-risk patients with aortic stenosis?
Does transcatheter aortic valve implantation (TAVI) improve haemodynamic and clinical outcomes in high-risk patients with aortic stenosis?
TAVI is a feasible treatment providing up to three years of clinical and haemodynamic improvement for high-risk aortic stenosis patients, though long-term durability remains to be established.
Supports TAVI consideration in high-risk aortic stenosis; leaves open durability and need for RCTs.
Seven years after the first-in-man transcatheter aortic valve implantation (TAVI) for the treatment of aortic stenosis, it remains a dynamic field of research and development. Evidence from 8,000 patients treated worldwide suggests that TAVI is feasible and provides haemodynamic and clinical improvement for up to three years in patients at high risk or with contraindications to surgery. Pending questions mainly concern safety and long-term durability. Today these techniques are targeted at high-risk patients, but they may be extended to lower-risk groups in the future if their initial promise holds true after careful evaluation.
No takes yet. Share an insight, caveat, or question.
Ducrocq et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: